Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22)

American Journal of Clinical Pathology

Volumn 140, Issue 4, 2013, Pages 525-535

  Johnson, Ryan C ^a   Savage, Natasha M ^b   Chiang, Tsoyu ^a   Gotlib, Jason R ^a   Cherry, Athena M ^a   Arber, Daniel A ^a   George, Tracy I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

AML with t(8; 21); CD25; D816V; Exon 17 KIT mutations; Myelomastocytic leukemia; N822K; Systemic mastocytosis; Tryptase

Indexed keywords

CD34 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; STEM CELL FACTOR RECEPTOR; TRYPTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CELL HYPERPLASIA; CHILD; CLINICAL ARTICLE; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; MALE; MAST CELL; MUTATIONAL ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SYSTEMIC MASTOCYTOSIS;

AML WITH T(8;21); CD25; D816V; EXON 17 KIT MUTATIONS; MYELOMASTOCYTIC LEUKEMIA; N822K; SYSTEMIC MASTOCYTOSIS; TRYPTASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; HYPERPLASIA; LEUKEMIA, MYELOID, ACUTE; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84884948790     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP1Q0YSXEAHNKK     Document Type: Article

References (36)

1. Arber DA, Brunning RD, LeBeau MM, et al. Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow SH, Harris NL, Jaffe ES, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:110-112.
2. Grimwade D, Walker H, Oliver F, et al, for the Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333. (Pubitemid 28452973)
3. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336. (Pubitemid 35429670)
4. Giebel LB, Strunk KM, Holmes SA, et al. Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. Oncogene. 1992;7:2207-2217.
5. Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am. 2000;14:517-535. (Pubitemid 30436932)
6. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal tumors. Science. 1998;279:577-580. (Pubitemid 28067289)
7. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340-4346. (Pubitemid 46630793)
8. Looijenga LHJ, de Leeuw H, van Oorshot M, et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res. 2003;63:7674-7678. (Pubitemid 37466695)
9. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92:10560-10564.
10. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113: 5727-5736.
11. Care RS, Valk PJM, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukemias. Br J Haematol. 2003;121:775-777. (Pubitemid 36718195)
12. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904-3911. (Pubitemid 46630738)
13. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791-1799. (Pubitemid 43289355)
14. Carioli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107:3463-3468.
15. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115:2372-2379.
16. Wong KF, Chan JCW, Kwong YL, et al. Concurrent acute myeloid leukemia and systemic mastocytosis. Am J Hematol. 1991;28:243-244.
17. Nagai S, Ichikawa M, Takahashi T, et al. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ ETO-positive acute myeloid leukemia. Exp Hematol. 2007;35:1747-1752. (Pubitemid 47633774)
18. Escribano L, García-Montero A, Núñez-LÓpez R, et al. Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis. J Allergy Clin Immunol. 2004;114:28-33. (Pubitemid 39005115)
19. Bernd HW, Sotlar K, Lorenzen J, et al. Acute myeloid leukemia with t(8;21) associated with "occult" mastocytosis: report of an unusual case and review of the literature. J Clin Pathol. 2004;57:324-328. (Pubitemid 38338852)
20. Pullarkat ST, Pullarkat V, Kroft SH, et al. Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia. J Hematop. 2009;2:27-33.
21. George TI, Horny HP. Systemic mastocytosis. Hematol Oncol Clin North Am. 2011;25:1067-1083.
22. Horny HP, Akin C, Metcalfe DD, et al. Systemic mastocytosis. In: Swerdlow SH, Harris NL, Jaffe ES, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:54-63.
23. Arredondo AR, Gotlib J, Shier L, et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol. 2010;85:600-606.
24. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74:121-132. (Pubitemid 46985284)
25. Horny HP, Sotlar K, Valent P. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology. 2010;77:169-180.
26. Krokowski M, Sotlar K, Krauth M-T, et al. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis. Am J Clin Pathol. 2005;124:560-568.
27. Sperr WR, Walchshofer S, Horny HP, et al. Systemic mastocytosis associated with acute myeloid leukemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Haematol. 1998;103:740-749. (Pubitemid 28545310)
28. Fritsche-Polanz R, Fritz M, Huber A, et al. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol. 2010;4:335-346.
29. Pullarkat V, Bedell V, Kim Y, et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res. 2007;31:261-265. (Pubitemid 44854181)
30. Sperr WR, Drach J, Hauswirth AW, et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemia clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res. 2005;11:6787-6792. (Pubitemid 41428732)
31. Kristensen T, Preiss B, Broesby-Olsen S, et al. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. Leuk Lymphoma. 2012;53:1338-1344.
32. Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162:737-746. (Pubitemid 36237482)
33. Schumacher JA, Elenitoba-Johnson KS, Lim MS. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR. J Clin Pathol. 2008;61:109-114. (Pubitemid 351158235)
34. Kristensen T, Broesby-Olsen S, Vestergaard H, et al. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol. 2012;89:42-46.
35. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435-453. (Pubitemid 46817344)
36. Wakita S, Yamaguchi H, Miyake K, et al. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 2011;25:1423-1432.